Amgen Inc. Stock Performance
Amgen Inc. shares closed at $385.65, reflecting a single-session decline of approximately 2.50%, per SID market data. The stock is currently trading below its 50-day moving average of $400.27, representing a discount of roughly 3.65% to that intermediate-term trend line. However, shares remain firmly above the 200-day moving average of $367.13, indicating the longer-term uptrend remains intact. Over the trailing twelve months, AMGN has gained 21.37%, while the one-month return stands at negative 12.82%, suggesting meaningful near-term selling pressure. The 14-day relative strength index registers at 27.4, placing the stock in oversold territory below the conventional 30 threshold, according to Massive/Polygon technical data. Amgen's beta of 0.472 confirms its historically low volatility relative to the broader market. Average daily trading volume stands at approximately 2.89 million shares, providing consistent liquidity for institutional participants navigating the current pullback.
Amgen Inc. Valuation Analysis
Amgen Inc. carries a market capitalization of approximately $209.2 billion, positioning it among the largest biotechnology companies globally, per SID market data. The stock trades at a price-to-earnings ratio of 27.13, which sits above the broader healthcare sector median, while the PEG ratio of 2.72 suggests the current earnings multiple is not fully supported by projected growth rates, according to SEC filings. The price-to-book ratio stands at 24.16, reflecting Amgen's significant goodwill and intangible assets accumulated through its acquisition-driven growth strategy, including the Horizon Therapeutics purchase. Amgen offers a dividend yield of approximately 2.49%, providing income-oriented investors with a return that exceeds the S&P 500 average yield. The combination of an elevated PEG ratio alongside a relatively modest earnings growth trajectory indicates that the current valuation prices in a premium for Amgen's established portfolio and pipeline, leaving limited margin for multiple expansion at present levels.
Smart Money Activity for AMGN
Amgen Inc. registers a smart money composite score of 51 out of 100, reflecting a neutral overall signal, per SID market data. The institutional component scores a perfect 25 out of 25, indicating robust and sustained positioning by large asset managers and pension funds. In contrast, the insider trading component scores 8.6 out of 25, with SEC Form 4 filings revealing 15 insider transactions over the past 90 days — comprising 9 purchases and 6 sales. The net insider buying modestly favors accumulation, though the relatively low insider score suggests transaction sizes may be limited. Dark pool activity registers at 10.5 out of 25, indicating moderate off-exchange institutional interest without signaling aggressive block accumulation. Congressional trading activity scores 6.8 out of 25, reflecting minimal notable positioning by legislators, according to 13F institutional filings. The divergence between the maximum institutional score and modest insider activity presents a mixed picture, with large funds maintaining conviction while corporate insiders demonstrate only moderate commitment at current price levels.
Amgen Inc. Earnings Outlook
Amgen Inc. has delivered three consecutive quarters of earnings beats, according to company earnings reports. In the most recently reported quarter, the company posted earnings per share of $6.29 against a consensus estimate of $5.60, representing a positive surprise of $0.69, or approximately 12.3%. The prior quarter produced EPS of $5.15 versus the $4.76 estimate, a $0.39 upside surprise, while the quarter before that delivered $5.29 against an expected $4.75, beating by $0.54. This pattern of consistent outperformance suggests disciplined cost management and stronger-than-anticipated commercial execution across Amgen's portfolio. The upcoming quarterly report carries an analyst consensus estimate of $4.81 per share, per analyst estimates. The sequential decline in the estimate relative to the most recent $6.29 result reflects typical seasonality patterns in Amgen's revenue mix. Investors will monitor whether the company can extend its earnings beat streak to four consecutive quarters.
Wall Street Analyst Ratings for AMGN
Wall Street sentiment toward Amgen Inc. has shifted notably in recent weeks, with multiple downgrades highlighting growing caution among sell-side analysts, per Wall Street analyst reports. HSBC downgraded AMGN from Buy to Hold on September 10, 2026, while BMO Capital moved its rating from Outperform to Market Perform on September 8, 2026. On the same date, Cantor Fitzgerald reiterated its Neutral stance. Wells Fargo maintained its Equal-Weight rating on September 4, 2026, and Piper Sandler maintained its Overweight rating on August 20, 2026, representing the sole bullish voice among recent coverage updates, according to SID consensus data. The clustering of two downgrades within a 48-hour period is notable, coinciding with the stock's 12.82% one-month decline. The prevailing tone across the five most recent analyst actions leans toward neutral-to-cautious, with three of five ratings now at hold-equivalent levels. Only Piper Sandler's Overweight recommendation reflects a constructive view on the stock's near-term trajectory.
